Dimerix (ASX:DXB) partnered with the UK's National Registry of Rare Kidney Diseases to identify patients for the Action3 phase 3 clinical trial, according to a Monday filing with the Australian bourse.
The trial aims to assess the efficacy and safety of the biopharmaceutical company's DMX-200 in treating a rare kidney condition called Focal Segmental Glomerulosclerosis, the filing stated. Recruitment is being done across 16 of the 19 planned countries, with a total recruitment target of 286 patients.
Additionally, Dimerix received approval for its Investigational New Drug Application from the Thai Food and Drug Administration, clearing a prerequisite for trial initiation. It expects clinical sites to begin recruitment in Thailand in the coming weeks.
The company's shares slipped past 1% in recent Monday trade.
Price (AUD): $0.41, Change: $-0.01, Percent Change: -1.20%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。